| Primary |
| Severe Acute Respiratory Syndrome |
23.2% |
| Interstitial Lung Disease |
8.4% |
| Asthma |
7.0% |
| Multiple Sclerosis |
7.0% |
| Immunosuppression |
6.5% |
| Prophylaxis Against Renal Transplant Rejection |
5.9% |
| Graft Versus Host Disease |
4.0% |
| Immunosuppressant Drug Therapy |
3.8% |
| Prophylaxis Against Graft Versus Host Disease |
3.8% |
| Nephrotic Syndrome |
3.5% |
| Dermatomyositis |
3.2% |
| Lupus Nephritis |
3.2% |
| Thymoma |
3.2% |
| Steroid Therapy |
3.0% |
| Prophylaxis |
2.7% |
| Lymphoma |
2.4% |
| Multiple Sclerosis Relapse |
2.4% |
| Preoperative Care |
2.4% |
| Anaemia Haemolytic Autoimmune |
2.2% |
| Systemic Lupus Erythematosus |
2.2% |
|
| Osteonecrosis |
34.4% |
| Sepsis |
7.0% |
| Pneumatosis Intestinalis |
5.5% |
| Hepatitis |
4.7% |
| Hyperglycaemia |
4.7% |
| Drug Ineffective |
3.9% |
| Posterior Reversible Encephalopathy Syndrome |
3.9% |
| Pyrexia |
3.9% |
| Atrial Fibrillation |
3.1% |
| Death |
3.1% |
| Pneumocystis Jiroveci Pneumonia |
3.1% |
| Respiratory Failure |
3.1% |
| Urticaria |
3.1% |
| Arteriospasm Coronary |
2.3% |
| Colitis Ischaemic |
2.3% |
| Diabetes Mellitus |
2.3% |
| Drug-induced Liver Injury |
2.3% |
| Osteoporosis |
2.3% |
| Pleural Effusion |
2.3% |
| Tremor |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
20.3% |
| Prophylaxis Against Renal Transplant Rejection |
14.9% |
| Renal Transplant |
11.1% |
| Prophylaxis Against Transplant Rejection |
8.1% |
| Hypertension |
6.0% |
| Prophylaxis |
5.8% |
| Drug Use For Unknown Indication |
4.6% |
| Acute Lymphocytic Leukaemia |
4.1% |
| Infection Prophylaxis |
3.9% |
| Premedication |
2.7% |
| Juvenile Arthritis |
2.5% |
| Acute Myeloid Leukaemia |
2.4% |
| Osteoporosis |
2.2% |
| Castleman's Disease |
1.9% |
| Prophylaxis Of Nausea And Vomiting |
1.8% |
| Interstitial Lung Disease |
1.8% |
| Dermatomyositis |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
| Multiple Sclerosis |
1.4% |
| Insomnia |
1.3% |
|
| Ureteric Stenosis |
28.9% |
| Kidney Transplant Rejection |
5.8% |
| Urinoma |
5.2% |
| Gastritis |
4.6% |
| Intestinal Perforation |
4.6% |
| Pulmonary Mycosis |
4.6% |
| Staphylococcal Sepsis |
4.6% |
| Ureteric Obstruction |
4.6% |
| Diabetes Mellitus |
4.0% |
| Drug Interaction |
4.0% |
| Thrombotic Microangiopathy |
4.0% |
| Pyrexia |
3.5% |
| Respiratory Failure |
3.5% |
| Caesarean Section |
2.9% |
| Cytolytic Hepatitis |
2.9% |
| Pulmonary Embolism |
2.9% |
| Generalised Oedema |
2.3% |
| Hepatitis |
2.3% |
| Juvenile Arthritis |
2.3% |
| Maternal Exposure During Pregnancy |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
18.8% |
| Prophylaxis |
16.2% |
| Infection Prophylaxis |
10.7% |
| Aplastic Anaemia |
9.3% |
| Premedication |
7.3% |
| Bone Marrow Conditioning Regimen |
6.7% |
| Prophylaxis Against Graft Versus Host Disease |
5.8% |
| Drug Use For Unknown Indication |
4.2% |
| Antifungal Prophylaxis |
3.4% |
| Antiviral Prophylaxis |
2.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.5% |
| Antibiotic Prophylaxis |
1.7% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Asthma |
1.5% |
| Hypertension |
1.4% |
| Constipation |
1.3% |
| Pneumonia |
1.1% |
| Insomnia |
1.0% |
|
| Pyrexia |
16.2% |
| White Blood Cell Count Decreased |
13.9% |
| Febrile Neutropenia |
6.4% |
| Sepsis |
6.4% |
| Staphylococcal Sepsis |
5.8% |
| Pneumonia |
5.4% |
| Multi-organ Failure |
4.1% |
| Thrombotic Microangiopathy |
4.1% |
| Vomiting |
4.1% |
| Liver Disorder |
3.5% |
| Respiratory Failure |
3.5% |
| Staphylococcal Infection |
3.5% |
| Asthma |
3.3% |
| Therapeutic Response Decreased |
3.1% |
| Neutropenia |
2.9% |
| Rash |
2.9% |
| Renal Failure |
2.9% |
| Thrombocytopenia |
2.9% |
| Cardiac Failure |
2.7% |
| Infection |
2.7% |
|
| Interacting |
| Pneumonia |
42.9% |
| Bronchospasm |
28.6% |
| Chronic Obstructive Pulmonary Disease |
14.3% |
| Muscle Relaxant Therapy |
14.3% |
|
| Myopathy |
66.7% |
| Tendon Rupture |
33.3% |
|
